Direct-to-consumer company tests FDA’s resolve on gene testing

CHICAGO (Reuters) – Just as 23andMe has made peace with the US Food and Drug Administration, another direct-to-consumer genetics company is testing the regulatory waters with the launch of a $249 DNA test designed to predict drug response.

—> Read More

facebooktwittergoogle_plusredditpinterestlinkedinmail